{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:29:19Z","timestamp":1790108959136,"version":"4.0.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European Alliance of Associations for Rheumatology","doi-asserted-by":"publisher","award":["QoC018"],"award-info":[{"award-number":["QoC018"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ard.2025.05.020","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T15:48:26Z","timestamp":1750780106000},"page":"1909-1927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of treatments in familial Mediterranean fever and its complications: a systematic review informing the EULAR\/PReS recommendations for familial Mediterranean fever"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6542-2656","authenticated-orcid":false,"given":"Erdal","family":"Sag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-7146","authenticated-orcid":false,"given":"Teresa","family":"Ot\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-2551","authenticated-orcid":false,"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2883-7868","authenticated-orcid":false,"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ard.2025.05.020_bib0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11926-017-0670-8","article-title":"Autoinflammatory diseases with periodic fevers","volume":"19","author":"Sag","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.ard.2025.05.020_bib0002","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00296-015-3408-9","article-title":"Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review","volume":"36","author":"Demirkaya","year":"2016","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.ard.2025.05.020_bib0003","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","article-title":"EULAR recommendations for the management of familial Mediterranean fever","volume":"75","author":"Ozen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.05.020_bib0004","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1093\/rheumatology\/keaa863","article-title":"Defining colchicine resistance\/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach","volume":"60","author":"\u00d6zen","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.05.020_bib0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"issue":"2","key":"10.1016\/j.ard.2025.05.020_bib0006","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"},{"key":"10.1016\/j.ard.2025.05.020_bib0007","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2025.05.020_bib0008","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]; 2013 [cited 2024 Sept 8]. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"4","key":"10.1016\/j.ard.2025.05.020_bib0009","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/art.39995","article-title":"Anakinra for colchicine-resistant familial mediterranean fever: a randomized, double-blind, placebo-controlled trial","volume":"69","author":"Ben-Zvi","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.ard.2025.05.020_bib0010","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1002\/art.38777","article-title":"Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study","volume":"66","author":"Brik","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"20","key":"10.1016\/j.ard.2025.05.020_bib0011","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ard.2025.05.020_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.55563\/clinexprheumatol\/e92f7o","article-title":"Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial","volume":"39","author":"Lachmann","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.05.020_bib0013","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2020-217419","article-title":"Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial","volume":"79","author":"Ozen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.05.020_bib0014","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","article-title":"Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial","volume":"157","author":"Hashkes","year":"2012","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.ard.2025.05.020_bib0015","first-page":"1535","article-title":"A randomised, double-blind, placebo-controlled phase III trial on the efficacy and safety of tocilizumab in patients with familial Mediterranean fever","volume":"40","author":"Koga","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"18","key":"10.1016\/j.ard.2025.05.020_bib0016","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.3390\/jcm11185360","article-title":"Tocilizumab for the treatment of familial Mediterranean fever-a randomized, double-blind, placebo-controlled phase II study","volume":"11","author":"Henes","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.ard.2025.05.020_bib0017","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/acr.23446","article-title":"Nationwide experience with off-label use of interleukin-1 targeting treatment in familial Mediterranean fever patients","volume":"70","author":"Akar","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.ard.2025.05.020_bib0018","doi-asserted-by":"crossref","first-page":"30","DOI":"10.55563\/clinexprheumatol\/815tdt","article-title":"Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients","volume":"39","author":"Atas","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.05.020_bib0019","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10067-018-4230-z","article-title":"On demand use of anakinra for attacks of familial Mediterranean fever (FMF)","volume":"38","author":"Babaoglu","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RHU.0000000000000873","article-title":"Effectiveness of canakinumab in colchicine- and anakinra-resistant or -intolerant adult familial Mediterranean fever patients: a single-center real-life study","volume":"26","author":"Babaoglu","year":"2020","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10753-014-0004-1","article-title":"Efficacy of interleukin-1 targeting treatments in patients with familial Mediterranean fever","volume":"38","author":"Cetin","year":"2015","journal-title":"Inflammation"},{"issue":"10","key":"10.1016\/j.ard.2025.05.020_bib0022","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00296-015-3293-2","article-title":"Treatment of colchicine-resistant familial Mediterranean fever in children and adolescents","volume":"35","author":"Eroglu","year":"2015","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0023","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00296-021-04997-y","article-title":"Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and\/or anakinra treatment","volume":"42","author":"Karabulut","year":"2022","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.ard.2025.05.020_bib0024","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/14397595.2016.1194510","article-title":"Anti-interleukin-1 treatment in 26 patients with refractory familial Mediterranean fever","volume":"27","author":"Kucuksahin","year":"2017","journal-title":"Mod Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.05.020_bib0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/1756-185X.13891","article-title":"\u00c7elikel Acar B. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: a single-center experience","volume":"23","author":"Kurt","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.05.020_bib0026","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1093\/rheumatology\/keaa728","article-title":"Anakinra for colchicine refractory familial Mediterranean fever: a cohort of 44 patients","volume":"60","author":"Marko","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0027","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12969-022-00784-6","article-title":"Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF","volume":"21","author":"Pinchevski-Kadir","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"issue":"11","key":"10.1016\/j.ard.2025.05.020_bib0028","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1093\/rheumatology\/keaa121","article-title":"Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry","volume":"59","author":"Sag","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s42358-020-0117-1","article-title":"Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant\/unresponsive familial Mediterranean fever","volume":"60","author":"\u015eahin","year":"2020","journal-title":"Adv Rheumatol"},{"issue":"12","key":"10.1016\/j.ard.2025.05.020_bib0030","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1093\/rheumatology\/keaa211","article-title":"Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever","volume":"59","author":"Ugurlu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ard.2025.05.020_bib0031","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/rheumatology\/keaa596","article-title":"Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience","volume":"60","author":"Ugurlu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2025.05.020_bib0032","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10067-018-4384-8","article-title":"Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients","volume":"38","author":"Varan","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.05.020_bib0033","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1097\/RHU.0000000000001271","article-title":"Protracted febrile myalgia syndrome treated with tocilizumab","volume":"27","author":"Honda","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0034","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13023-017-0642-0","article-title":"Tocilizumab in the treatment of twelve cases with AA amyloidosis secondary to familial Mediterranean fever","volume":"12","author":"Ugurlu","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.05.020_bib0035","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/rheumatology\/keu474","article-title":"Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever","volume":"54","author":"Yilmaz","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0036","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00296-019-04490-7","article-title":"Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review","volume":"40","author":"Karadeniz","year":"2020","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.ard.2025.05.020_bib0037","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/rheumatology\/key384","article-title":"Tofacitinib for familial Mediterranean fever: a new alternative therapy?","volume":"58","author":"Garcia-Robledo","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0038","first-page":"88","article-title":"Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever","volume":"42","author":"G\u00f6k","year":"2017","journal-title":"Acta Reumatol Port"},{"issue":"5","key":"10.1016\/j.ard.2025.05.020_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105201","article-title":"Familial Mediterranean fever (FMF)-response to TNF-blockers used for treatment of FMF patients with concurrent inflammatory diseases","volume":"88","author":"Haj-Yahia","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ard.2025.05.020_bib0040","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/854842","article-title":"The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever","volume":"2014","author":"Hashkes","year":"2014","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.ard.2025.05.020_bib0041","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/14397595.2018.1457469","article-title":"Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis","volume":"29","author":"Varan","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.05.020_bib0042","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/14397595.2020.1790139","article-title":"Do all colchicine preparations have the same effectiveness in patients with familial Mediterranean fever?","volume":"31","author":"Baglan","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0043","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00296-019-04432-3","article-title":"Different pharmaceutical preparations of colchicine for familial Mediterranean fever: are they the same?","volume":"40","author":"Emmungil","year":"2020","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0044","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4274\/balkanmedj.galenos.2020.2020.5.2205.220","article-title":"Comparison of different pharmaceutical preparations of colchicine in children with familial Mediterranean fever: is colchicine opocalcium a good alternative?","volume":"38","author":"T\u00fcrku\u00e7ar","year":"2021","journal-title":"Balkan Med J"},{"issue":"8","key":"10.1016\/j.ard.2025.05.020_bib0045","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1016\/j.jaip.2021.03.048","article-title":"Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: a national multicenter longitudinal study","volume":"9","author":"Bustaffa","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.ard.2025.05.020_bib0046","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.semarthrit.2019.05.011","article-title":"Age dependent safety and efficacy of colchicine treatment for familial Mediterranean fever in children","volume":"49","author":"Goldberg","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.05.020_bib0047","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-016-0980-7","article-title":"Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever\u2013a randomized controlled noninferiority trial","volume":"18","author":"Polat","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.05.020_bib0048","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpeds.2020.03.065","article-title":"Colchicine and leukopenia: clinical implications","volume":"224","author":"Sag","year":"2020","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.ard.2025.05.020_bib0049","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3906\/sag-2001-261","article-title":"Colchicine intolerance in FMF patients and primary obstacles for optimal dosing","volume":"50","author":"Sati\u015f","year":"2020","journal-title":"Turk J Med Sci"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00296-020-04721-2","article-title":"Menorrhagia due to uterine amyloidosis in familial Mediterranean fever: case-based review","volume":"41","author":"Cansu","year":"2021","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.ard.2025.05.020_bib0051","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40272-019-00354-6","article-title":"Canakinumab in children with familial Mediterranean fever: a single-center, retrospective analysis","volume":"21","author":"Kisla Ekinci","year":"2019","journal-title":"Paediatr Drugs"},{"issue":"2","key":"10.1016\/j.ard.2025.05.020_bib0052","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/1756-185X.13250","article-title":"Efficacy of anakinra in a patient with systemic amyloidosis presenting as amyloidoma","volume":"21","author":"Nalcacioglu","year":"2018","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0053","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1590\/1516-3180.2018.0311101218","article-title":"Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis","volume":"137","author":"Sargin","year":"2019","journal-title":"Sao Paulo Med J"},{"issue":"5","key":"10.1016\/j.ard.2025.05.020_bib0054","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00296-018-3993-5","article-title":"Canakinumab treatment in children with familial Mediterranean fever: report from a single center","volume":"38","author":"Yaz\u0131l\u0131ta\u015f","year":"2018","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.ard.2025.05.020_bib0055","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.nefroe.2022.01.002","article-title":"Baseline renal functions predict the effect of canakinumab on regression of proteinuria in patients with familial Mediterranean fever","volume":"41","author":"Yildirim","year":"2021","journal-title":"Nefrologia (Engl Ed)"},{"issue":"12","key":"10.1016\/j.ard.2025.05.020_bib0056","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2169\/internalmedicine.2277-18","article-title":"Atypical familial Mediterranean fever complicated with gastrointestinal amyloidosis diagnosed due to paroxysmal arthralgia and intractable diarrhea, successfully treated with tocilizumab","volume":"58","author":"Aikawa","year":"2019","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.ard.2025.05.020_bib0057","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/14397595.2014.908810","article-title":"Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever","volume":"26","author":"Hamanoue","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.05.020_bib0058","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/24725625.2020.1739193","article-title":"Long term administration of tocilizumab improves renal amyloid A (AA) amyloidosis deposition in familial Mediterranean fever","volume":"4","author":"Inui","year":"2020","journal-title":"Mod Rheumatol Case Rep"},{"issue":"6","key":"10.1016\/j.ard.2025.05.020_bib0059","first-page":"S169","article-title":"Remission of nephrotic syndrome due to AA-amyloidosis, complicating familiar Mediterranean fever, with tocilizumab","volume":"33","author":"Serelis","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.05.020_bib0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.nefroe.2020.10.001","article-title":"A familial Mediterranean fever patient with double homozygous mutations treated with anakinra after kidney transplantation","volume":"40","author":"Hasbal","year":"2020","journal-title":"Nefrologia (Engl Ed)"},{"issue":"5","key":"10.1016\/j.ard.2025.05.020_bib0061","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfac335","article-title":"Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score-matched cohort study","volume":"38","author":"Mirioglu","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.ard.2025.05.020_bib0062","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/tri.13312","article-title":"Transplantation within the era of anti-IL-1 therapy: case series of five patients with familial Mediterranean fever-related amyloidosis","volume":"31","author":"\u00d6z\u00e7akar","year":"2018","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.ard.2025.05.020_bib0063","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10067-014-2772-2","article-title":"Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis","volume":"35","author":"\u00d6z\u00e7akar","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.05.020_bib0064","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12881-017-0457-9","article-title":"Living kidney transplantation between brothers with unrecognized renal amyloidosis as the first manifestation of familial Mediterranean fever: a case report","volume":"18","author":"Peces","year":"2017","journal-title":"BMC Med Genet"},{"issue":"7","key":"10.1016\/j.ard.2025.05.020_bib0065","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.transproceed.2019.03.049","article-title":"Outcomes of canakinumab treatment in recipients of kidney transplant with familial Mediterranean fever: a case series","volume":"51","author":"Sendogan","year":"2019","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.ard.2025.05.020_bib0066","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14309","article-title":"The efficacy of interleukin-1 antagonist drugs in combination with colchicine in patients with FMF-AA with colchicine resistance after kidney transplantation: a study with histopathologic evidence","volume":"35","author":"Simsek","year":"2021","journal-title":"Clin Transplant"},{"issue":"8","key":"10.1016\/j.ard.2025.05.020_bib0067","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13345","article-title":"Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever","volume":"32","author":"Trabulus","year":"2018","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.ard.2025.05.020_bib0068","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40620-018-0475-5","article-title":"Canakinumab treatment in renal transplant recipients with familial Mediterranean fever","volume":"31","author":"Yildirim","year":"2018","journal-title":"J Nephrol"},{"issue":"2","key":"10.1016\/j.ard.2025.05.020_bib0069","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/rheumatology\/kead465","article-title":"Characteristics and course of patients with AA amyloidosis: single centre experience with 174 patients from Turkey","volume":"63","author":"Bektas","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2025.05.020_bib0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.ajkd.2023.07.020","article-title":"Kidney transplantation in patients with AA amyloidosis: outcomes in a French multicenter cohort","volume":"83","author":"Schwarz","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 2","key":"10.1016\/j.ard.2025.05.020_bib0071","first-page":"65","article-title":"Efficacy, safety, pharmacokinetics and pharmacodynamics of canakinumab in patients with colchicine-resistant FMF: results from the phase 3 cluster trial","volume":"15","author":"Ozen","year":"2017","journal-title":"Pediatr Rheumatol"},{"issue":"11","key":"10.1016\/j.ard.2025.05.020_bib0072","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.3390\/ijms24119584","article-title":"An update on familial Mediterranean fever","volume":"24","author":"Lancieri","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.ard.2025.05.020_bib0073","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1093\/rheumatology\/keaa205","article-title":"A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever","volume":"59","author":"Kuemmerle-Deschner","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2025.05.020_bib0074","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/rheumatology\/kead514","article-title":"Efficacy and safety of anti-interleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis","volume":"63","author":"Kilic","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2025.05.020_bib0075","article-title":"Interventions for reducing inflammation in familial Mediterranean fever","volume":"3","author":"Yin","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ard.2025.05.020_bib0076","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.956795","article-title":"Interleukin-6 inhibition in the treatment of autoinflammatory diseases","volume":"13","author":"Koga","year":"2022","journal-title":"Front Immunol"},{"issue":"4 Suppl 34","key":"10.1016\/j.ard.2025.05.020_bib0077","first-page":"S34","article-title":"Levels of interleukin-6 (IL-6) and its soluble receptor (sIL-6R) in familial Mediterranean fever (FMF) patients and their first degree relatives","volume":"22","author":"Oktem","year":"2004","journal-title":"Clin Exp Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725010349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725010349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:15:37Z","timestamp":1779855337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725010349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0003496725010349"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.05.020","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of treatments in familial Mediterranean fever and its complications: a systematic review informing the EULAR\/PReS recommendations for familial Mediterranean fever","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}